Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr;67(4):1367-1381.
doi: 10.1007/s12033-024-01151-4. Epub 2024 Apr 29.

The Role of HSP90 and TRAP1 Targets on Treatment in Hepatocellular Carcinoma

P K Praveen Kumar  1   2 , Harini Sundar  3 , Kamalavarshini Balakrishnan  3 , Sakthivel Subramaniam  3 , Hemalatha Ramachandran  3 , M Kevin  3 , M Michael Gromiha  4
Affiliations
Review

The Role of HSP90 and TRAP1 Targets on Treatment in Hepatocellular Carcinoma

P K Praveen Kumar et al. Mol Biotechnol. 2025 Apr.

Abstract

Hepatocellular Carcinoma (HCC) is the predominant form of liver cancer and arises due to dysregulation of the cell cycle control machinery. Heat Shock Protein 90 (HSP90) and mitochondrial HSP90, also referred to as TRAP1 are important critical chaperone target receptors for early diagnosis and targeting HCC. Both HSP90 and TRAP1 expression was found to be higher in HCC patients. Hence, the importance of HSP90 and TRAP1 inhibitors mechanism and mitochondrial targeted delivery of those inhibitors function is widely studied. This review also focuses on importance of protein-protein interactions of HSP90 and TRAP1 targets and association of its interacting proteins in various pathways of HCC. To further elucidate the mechanism, systems biology approaches and computational biology approach studies are well explored in the association of inhibition of herbal plant molecules with HSP90 and its mitochondrial type in HCC.

Keywords: Heat Shock Protein 90; Hepatocellular Carcinoma; Mitochondrial Targeting; Systems Biology; Tumor Necrosis Factor associated with Protein-1.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors claim no conflict of interests.

References

    1. Chae, Y. C., Angelin, A., Lisanti, S., Kossenkov, A. V., Speicher, K. D., Wang, H., Powers, J. F., Tischler, A. S., Pacak, K., Fliedner, S., Michalek, R. D., Karoly, E. D., Wallace, D. C., Languino, L. R., Speicher, D. W., & Altieri, D. C. (2013). Landscape of the mitochondrial Hsp90 metabolome in tumours. Nature Communications, 4(1), 1–9.
    1. Siegelin, M. D., Dohi, T., Raskett, C. M., Orlowski, G. M., Powers, C. M., Gilbert, C. A., Ross, A. H., Plescia, J., & Altieri, D. (2011). Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. Journal of Clinical Investigation, 121(4), 1349–1360. - PubMed - PMC
    1. Dong, L., Gopalan, V., Holland, O., & Neuzil, J. (2020). Mitocans revisited: Mitochondrial targeting as efficient anti-cancer therapy. International Journal of Molecular Sciences, 21(21), 7941. - PubMed - PMC
    1. Esner, M., Graifer, D., Lleonart, M. E., & Lyakhovich, A. (2017). Targeting cancer cells through antibiotics-induced mitochondrial dysfunction requires autophagy inhibition. Cancer Letters, 384, 60–69. - PubMed
    1. Battogtokh, G., Cho, Y.-Y., Lee, J. Y., Lee, H. S., & Kang, H. C. (2018). Mitochondrial-targeting anticancer agent conjugates and nanocarrier systems for cancer treatment. Frontiers in Pharmacology, 9, 1–20.

MeSH terms

LinkOut - more resources